If approved in the U.S., IGEA’s products will be marketed under the Orthofix brand.
The IGEA products will strengthen Orthofix’s bone growth portfolio, which includes pulsed electromagnetic field products with treatment options such as low-intensity pulsed ultrasound and capacitive coupling for fracture management.
The partnership also includes new technology applications for joint inflammation, pain and cartilage protection.
The combined portfolios will advance Orthofix’s “treatment solutions for fracture management and complement our pursuit of new indications for managing soft tissue and joint health such as our ongoing rotator cuff repair IDE clinical study,” Jon Serbousek, president and CEO of Orthofix, said in an April 28 news release.
More articles on devices:
Why more spine surgeons are looking to invest in ASCs
‘A game-changer’: One spine surgeon’s experience relocating from Brazil to the U.S.
$33M flagship facility opened by 25-physician orthopedic group
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
